Carpe Diem
Tag: mRNA-4157
Cancer Vaccines: Moderna & Merck's Breakthrough Opens the Door to 500+ Candidates 🧬💉
🧬💉 Moderna ($MRNA) and Merck ($MRK) have achieved a landmark Phase III success in personalized cancer vaccination, reducing the relative risk of melanoma recurrence or death by 42% when combined with Keytruda. But here's the truly extraordinary part: more than 500 cancer vaccine candidates are already in development worldwide. Many questions remain, and nothing is guaranteed. Yet the scientific possibilities have rarely looked more exciting. Carpe Diem! ❤️
Quick links
Search
About/Leadership
Editorial Process
Privacy Policy
Refund Policy
Shipping Policy
Terms of Service
Contact us
About us
FUNanc!al distills the fun in finance and the finance in fun, makes news personal, and helps all reach happiness.
